Ariel R. Topletz‐Erickson

Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl

L. Wienkers, C. Endres, S. Alley, 2022, Cancer Chemotherapy and Pharmacology.

Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers

C. Endres, L. Walker, Anthony Lee, 2022, Clinical Pharmacokinetics.